Page last updated: 2024-12-11
pradefovir mesylate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
pradefovir: a HepDirect prodrug of adefovir; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9604653 |
CHEMBL ID | 3989658 |
MeSH ID | M0482044 |
Synonyms (29)
Synonym |
---|
625095-61-6 |
pradefovir mesylate (usan) |
D05588 |
remofovir mesylate |
icn-2001-3 |
mb-6866 |
pradefovir mesylate |
hepavir b |
mb-06866 , |
mb-06866q |
9-(2-(4-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl)methoxyethyl)adenine |
pradefovir mesylate [usan] |
9h-purin-6-amine, 9-(2-(((2r,4s)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl)-methoxy)ethyl)-, monomethanesulfonate; |
unii-0d5204zsix |
mb 06866q |
0d5204zsix , |
pradefovir |
pradefovir mesilate [who-dd] |
pradefovir mesilate |
DB05478 |
DTXSID00211558 |
mb6866 |
CHEMBL3989658 |
Q27095685 |
HY-112690A |
CS-0062746 |
pradefovir mesylate (remofovir mesylate) |
EX-A1921 |
9-[2-[[(2r,4s)-4-(3-chlorophenyl)-2-oxo-1,3,2lambda5-dioxaphosphinan-2-yl]methoxy]ethyl]purin-6-amine;methanesulfonic acid |
Research Excerpts
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" No subject experienced a serious adverse event or nephrotoxicity." | ( Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection. Chen, H; Ding, Y; Jin, W; Li, C; Li, X; Liu, C; Liu, J; Niu, J; Wu, M; Zhang, D; Zhang, H; Zhu, X, 2020) | 0.56 |
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" The half-life of PMEA in the pradefovir group was 11." | ( Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection. Chen, H; Ding, Y; Jin, W; Li, C; Li, X; Liu, C; Liu, J; Niu, J; Wu, M; Zhang, D; Zhang, H; Zhu, X, 2020) | 0.56 |
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" Oral absorption and bioavailability were 29." | ( Single-dose pharmacokinetics and metabolism of [14C]remofovir in rats and cynomolgus monkeys. Lin, CC; Lourenco, D; Xu, C; Yeh, LT; Zhu, N, 2005) | 0.33 |
" The lead prodrug (14, MB06866, pradefovir), identified from a variety of in vitro and in vivo assays, exhibited good oral bioavailability (F = 42%, mesylate salt, rat) and rate of prodrug conversion to ADV-DP." | ( Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B. Boyer, SH; Colby, TJ; Craigo, W; DaRe, J; Erion, MD; Fujitaki, JM; Gómez-Galeno, JE; Matelich, MC; Ollis, K; Reddy, KR; Sun, Z; Ugarkar, BG; van Poelje, PD, 2008) | 0.35 |
Dosage Studied
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (12)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (66.67) | 29.6817 |
2010's | 2 (16.67) | 24.3611 |
2020's | 2 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.63
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.63) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 4 (33.33%) | 5.53% |
Reviews | 1 (8.33%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (58.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |